Nuvation Bio Inc [NYSE: NUVB] stock went on an upward path that rose over 6179800% on Tuesday, amounting to a one-week price increase of more than 10.22%.
Over the last 12 months, NUVB stock dropped by -22.93%. The one-year Nuvation Bio Inc stock forecast points to a potential downside of -61195828.75. The average equity rating for NUVB stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $697.54 million, with 338.84 million shares outstanding and 226.12 million shares in the current float. Compared to the average trading volume of 4.81M shares, NUVB stock reached a trading volume of 6179800 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Nuvation Bio Inc [NUVB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NUVB shares is $7.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NUVB stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citizens JMP have made an estimate for Nuvation Bio Inc shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on April 23, 2025. While these analysts kept the previous recommendation, Jefferies raised their target price from $1.40 to $10. The new note on the price target was released on March 27, 2024, representing the official price target for Nuvation Bio Inc stock. Previously, the target price had yet another raise to $5, while BTIG Research analysts kept a Buy rating on NUVB stock. On January 06, 2023, analysts decreased their price target for NUVB shares from 5 to 2.
The Price to Book ratio for the last quarter was 1.66, with the Price to Cash per share for the same quarter was set at 1.36.
NUVB Stock Performance Analysis:
Nuvation Bio Inc [NUVB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 10.22. With this latest performance, NUVB shares dropped by -8.89% in over the last four-week period, additionally sinking by -21.46% over the last 6 months – not to mention a drop of -22.93% in the past year of trading.
Insight into Nuvation Bio Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Nuvation Bio Inc [NUVB] shares currently have an operating margin of -1883.38% and a Gross Margin at 7.76%. Nuvation Bio Inc’s Net Margin is presently recorded at -5534.21%.
Return on Equity for this stock declined to -109.69%, with Return on Assets sitting at -109.69%.
NUVB Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NUVB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Nuvation Bio Inc go to 38.04%.
Nuvation Bio Inc [NUVB] Institutonal Ownership Details
There are presently around $61.81%, or 76.44% of NUVB stock, in the hands of institutional investors. The top three institutional holders of NUVB stocks are: FMR LLC with ownership of 28.82 million shares, which is approximately 11.7767%. ECOR1 CAPITAL, LLC, holding 19.21 million shares of the stock with an approximate value of $$56.09 million in NUVB stocks shares; and ECOR1 CAPITAL, LLC, currently with $$47.41 million in NUVB stock with ownership which is approximately 6.6343%.
